Methamphetamine is known to produce teeth grinding, a physical effect. An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that produces a compulsive need to clench, chew, or gnash the teeth together. This effect can range from a subtle tightness in the jaw to forceful, repetitive grinding that can cause significant dental damage and jaw pain during and after the experience.
Teeth grinding, or bruxism, is experienced as an involuntary tightening of the masseter and temporalis muscles that control jaw movement. From a first-person perspective, it begins as a subtle tension or "buzzing" sensation in the jaw that gradually intensifies into a compulsive need to clench the teeth together or move the jaw in rhythmic grinding motions. Many users describe the sensation as oddly satisfying in the moment despite knowing it is harmful — the jaw seems to seek pressure and resistance, and chewing on gum, bottle caps, or the inside of one's cheeks becomes almost automatic.
The severity of teeth grinding scales predictably with dose. At low doses, it may manifest as occasional jaw tightness or catching oneself clenching intermittently. At moderate doses, the grinding becomes persistent and difficult to suppress voluntarily — relaxing the jaw requires conscious effort and the tension returns within seconds. At high doses, the grinding can become forceful enough to chip teeth, cause TMJ (temporomandibular joint) pain, and produce significant soreness in the jaw muscles that persists for days after the experience.
There are two primary patterns of substance-induced bruxism. The first is rhythmic grinding, where the jaw moves in repetitive lateral or front-to-back motions, often unconsciously. The second is tonic clenching, where the jaw locks in a sustained bite with tremendous force. Some users experience both patterns alternating throughout an experience. The grinding is often accompanied by other oral behaviors such as lip chewing, tongue pressing against the teeth, and compulsive gum chewing.
The mechanism underlying substance-induced bruxism is primarily serotonergic and dopaminergic in nature. Increased serotonin activity, particularly at 5-HT2A receptors, appears to drive jaw muscle hyperactivity. Dopamine release in the basal ganglia, which controls motor patterns, contributes to the repetitive, compulsive nature of the movement. This is why the effect is most pronounced with substances that strongly increase both serotonin and dopamine, such as MDMA and amphetamines.
Teeth grinding is most strongly associated with MDMA and other empathogens, where it is nearly universal at moderate-to-high doses. It is also common with amphetamines, methamphetamine, cocaine, and synthetic cathinones. Certain psychedelics, particularly those with stimulant properties like the 2C-x family and DOx compounds, can produce notable bruxism. High doses of caffeine and other xanthines can also produce mild jaw tension.
Harm reduction for teeth grinding centers on protecting the teeth and jaw. Magnesium supplementation (glycinate or citrate, 200-400mg) taken before the experience can significantly reduce jaw tension. Chewing gum provides a safer outlet for the grinding urge than clenching on bare teeth, though excessive gum chewing can still fatigue the jaw muscles. Mouth guards designed for bruxism offer the best dental protection. Avoiding combining multiple serotonergic stimulants reduces severity. Persistent jaw pain or clicking after use warrants dental consultation.
Teeth grinding can manifest at varying intensities depending on the dose of Methamphetamine and individual sensitivity. The following levels describe the typical progression of this effect.
Occasional, subtle jaw tightness that one may not notice unless paying attention. Easily suppressed voluntarily.
Noticeable jaw tension and periodic clenching. One catches oneself grinding occasionally. Gum or something to chew on becomes desirable.
Persistent, difficult-to-suppress grinding and clenching. Jaw tension is constant and relaxing requires conscious effort. Chewing feels compulsive.
Forceful, involuntary grinding that is nearly impossible to stop. Significant jaw fatigue and soreness develop. Risk of dental damage becomes real.
Extreme, uncontrollable jaw clenching with tremendous force. Teeth may chip or crack. Severe jaw pain and potential TMJ injury. Jaw muscles may spasm.
Pharmacodynamics
Methamphetamine has been identified as a potent full agonist of trace amine-associated receptor 1 (TAAR1), a G protein-coupled receptor (GPCR) that regulates brain catecholamine systems. Activation of TAAR1 increases cyclic adenosine monophosphate (cAMP) production and either completely inhibits or reverses the transport direction of the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). When methamphetamine binds to TAAR1, it triggers transporter phosphorylation via protein kinase A (PKA) and protein kinase C (PKC) signaling, ultimately resulting in the internalization or reverse function of monoamine transporters. Methamphetamine is also known to increase intracellular calcium, an effect which is associated with DAT phosphorylation through a Ca2+/calmodulin-dependent protein kinase (CAMK)-dependent signaling pathway, in turn producing dopamine efflux. TAAR1 has been shown to reduce the firing rate of neurons through direct activation of G protein-coupled inwardly-rectifying potassium channels. TAAR1 activation by methamphetamine in astrocytes appears to negatively modulate the membrane expression and function of EAAT2, a type of glutamate transporter.
In addition to its effect on the plasma membrane monoamine transporters, methamphetamine inhibits synaptic vesicle function by inhibiting VMAT2, which prevents monoamine uptake into the vesicles and promotes their release. Methamphetamine binds to VMAT2 via the resperine site, in contrast to amphetamine, which appears to bind at the tetrabenazine site. This results in the outflow of monoamines from synaptic vesicles into the cytosol (intracellular fluid) of the presynaptic neuron, and their subsequent release into the synaptic cleft by the phosphorylated transporters. Other transporters that methamphetamine is known to inhibit are SLC22A3 and SLC22A5. SLC22A3 is an extraneuronal monoamine transporter that is present in astrocytes, and SLC22A5 is a high-affinity carnitine transporter.
Methamphetamine is also an agonist of the alpha-2 adrenergic receptors and sigma receptors with a greater affinity for σ1 than σ2, and inhibits monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). Sigma receptor activation by methamphetamine may facilitate its central nervous system stimulant effects and promote neurotoxicity within the brain. Dextromethamphetamine is a stronger psychostimulant, but levomethamphetamine has stronger peripheral effects, a longer half-life, and longer perceived effects among heavy substance users. At high doses, both enantiomers of methamphetamine can induce similar stereotypy and methamphetamine psychosis, but levomethamphetamine has shorter psychodynamic effects.
Pharmacokinetics
The bioavailability of methamphetamine is 67% orally, 79% intranasally, 67 to 90% via inhalation (smoking), and 100% intravenously. Following oral administration, methamphetamine is well-absorbed into the bloodstream, with peak plasma methamphetamine concentrations achieved in approximately 3.13–6.3hours post ingestion. Methamphetamine is also well absorbed following inhalation and following intranasal administration. Because of the high lipophilicity of methamphetamine due to its methyl group, it can readily move through the blood–brain barrier faster than other stimulants, where it is more resistant to degradation by monoamine oxidase. The amphetamine metabolite peaks at 10–24hours. Methamphetamine is excreted by the kidneys, with the rate of excretion into the urine heavily influenced by urinary pH. When taken orally, 30–54% of the dose is excreted in urine as methamphetamine and 10–23% as amphetamine. Following IV doses, about45% is excreted as methamphetamine and 7% as amphetamine. The elimination half-life of methamphetamine varies with a range of 5–30hours, but it is on average 9 to 12hours in most studies. The elimination half-life of methamphetamine does not vary by route of administration, but is subject to substantial interindividual variability.
CYP2D6, dopamine β-hydroxylase, flavin-containing monooxygenase 3, butyrate-CoA ligase, and glycine N-acyltransferase are the enzymes known to metabolize methamphetamine or its metabolites in humans. The primary metabolites are amphetamine and 4-hydroxymethamphetamine; other minor metabolites include: 4-hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, benzoic acid, hippuric acid, norephedrine, and phenylacetone, the metabolites of amphetamine. Among these metabolites, the active sympathomimetics are amphetamine, 4‑hydroxyamphetamine, 4‑hydroxynorephedrine, 4-hydroxymethamphetamine, and norephedrine. Methamphetamine is a CYP2D6 inhibitor.
The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination. The known metabolic pathways include:
Detection in biological fluids
Methamphetamine and amphetamine are often measured in urine or blood as part of a drug test for sports, employment, poisoning diagnostics, and forensics. Chiral techniques may be employed to help distinguish the source of the drug to determine whether it was obtained illicitly or legally via prescription or prodrug. Chiral separation is needed to assess the possible contribution of levomethamphetamine, which is an active ingredients in some OTC nasal decongestants, toward a positive test result. Dietary zinc supplements can mask the presence of methamphetamine and other drugs in urine.
Methamphetamine can be administered via insufflated, intravenous, oral, rectal, smoked. The route of administration can influence both the onset and intensity of teeth grinding.
The intensity of teeth grinding depends heavily on the dose of Methamphetamine. Effects like teeth grinding are typically reported at common to strong doses. Below is the full dosage chart for Methamphetamine.
Warning
Severe teeth grinding can crack or chip teeth, damage dental work, and cause temporomandibular joint (TMJ) disorder. Chronic substance-induced bruxism can lead to permanent dental damage and jaw problems. Magnesium supplementation and mouth guards are recommended harm reduction measures.
Yes. Teeth grinding is a documented physical effect of Methamphetamine. An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that produces a compulsive need to clench, chew, or gnash the teeth together. This effect can range from a subtle tightness in the jaw to forceful, repetitive grinding that can cause significant dental damage and jaw pain during and after the experience.
Effects like teeth grinding are typically reported at common doses and above. A common insufflated dose of Methamphetamine is 10–30 mg.
Other substances documented to produce teeth grinding include MDMA, Cocaine, Amphetamine, 1P-LSD, 1P-ETH-LAD, and 35 more.